Nexalin’s $5M Raise Sparks 34% Stock Surge as FDA Push Intensifies

Introduction to NEXALIN TECHNOLOGY INC

Nexalin Technology Inc. (Nasdaq: NXL), headquartered in Houston, Texas, develops non-invasive neurostimulation devices aimed at treating anxiety, insomnia, depression, and other brain-based conditions. Its patented waveform technology (U.S. Patent No. 6,904,322 B2) targets deep midbrain centers to address neurochemical irregularities without medication.

Corporate Structure

As of August 2025, Nexalin employs between 11 and 50 people. Key executives include Mark White (President), Carolyn Shelton (Chief Operating Officer), Kristin H. (Chief of Staff), and Ashwani Kumar (Project Manager). The company supports at-home administration of its treatments under FDA-cleared protocols.

Neurostimulation by David Matos

Recent Developments and News

On May 6, 2025, Nexalin closed an underwritten public offering of 3,850,000 shares at $1.30 per share, raising approximately $5 million to advance its Deep Intracranial Frequency Stimulation (DIFS™) products.
On July 21 and August 4, 2025, the company filed current reports on Form 8-K (Items 5.02 and 9.01), indicating changes in executive roles. On August 6, 2025, Nexalin submitted its Form 10-Q for the quarter ended June 30, 2025, outlining financial results and operational updates. As of August 22, 2025, the stock trades at $0.9805—up 34.32% on a volume of 1,006,300 shares on the NASDAQ.

Financial and Strategic Analysis

The $5 million raised through the May public offering enhances working capital for research and development activities. International approvals in China, Brazil, and Oman indicate market acceptance outside of the United States. Insider purchases by executives such as Chief Medical Officer David Owens and Senior VP Carolyn Shelton indicate confidence in the company’s direction. In the fourth quarter of 2024, institutional investors showed mixed activity: Vanguard Group increased its holdings by 294.8%, while Renaissance Technologies and Citadel Advisors fully exited positions.

Strategically, Nexalin addresses a substantial market: approximately 40 million Americans with chronic insomnia, 18% of adults experiencing anxiety disorders, and 200,000 individuals living with early-onset Alzheimer’s disease. The company is pursuing FDA clearance for treatments related to Alzheimer’s and substance use disorders and positions itself without direct competitors in the neurostimulation sector.

Market Position and Industry Context

Nexalin operates within the broader brain health technology space, which traditionally relies on pharmaceuticals and psychotherapy. Its device provides an alternative treatment method with reported symptom reductions of 60%–80% in patient surveys. By facilitating treatment in both clinical and home settings, Nexalin aims to address barriers associated with cost, stigma, and side effects linked to existing therapies.

tl;dr

Since May 6, 2025, when Nexalin raised $5 million via a public offering at $1.30 per share, the company has filed multiple SEC reports (Form 8-K and Form 10-Q) and seen its share price rise by 34.32% to $0.9805 as of August 22, 2025. Looking ahead, Nexalin is advancing FDA submissions for Alzheimer’s and addiction treatments while leveraging international approvals to expand its deep intracranial frequency stimulation platform.